JPH0124135B2 - - Google Patents
Info
- Publication number
- JPH0124135B2 JPH0124135B2 JP61243657A JP24365786A JPH0124135B2 JP H0124135 B2 JPH0124135 B2 JP H0124135B2 JP 61243657 A JP61243657 A JP 61243657A JP 24365786 A JP24365786 A JP 24365786A JP H0124135 B2 JPH0124135 B2 JP H0124135B2
- Authority
- JP
- Japan
- Prior art keywords
- surgery
- pain
- cells
- wound
- bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 208000027418 Wounds and injury Diseases 0.000 claims description 40
- 206010052428 Wound Diseases 0.000 claims description 33
- 238000001356 surgical procedure Methods 0.000 claims description 33
- 208000014674 injury Diseases 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 230000008733 trauma Effects 0.000 claims description 17
- 150000002926 oxygen Chemical class 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 38
- 208000002193 Pain Diseases 0.000 description 33
- 230000036407 pain Effects 0.000 description 33
- 150000002500 ions Chemical class 0.000 description 32
- 208000032843 Hemorrhage Diseases 0.000 description 27
- 230000000740 bleeding effect Effects 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 18
- 230000035876 healing Effects 0.000 description 17
- 210000000170 cell membrane Anatomy 0.000 description 16
- 210000004204 blood vessel Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 210000003712 lysosome Anatomy 0.000 description 7
- 230000001868 lysosomic effect Effects 0.000 description 7
- 229910052709 silver Inorganic materials 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- 230000036982 action potential Effects 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- -1 chemotherapy drugs Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 4
- 229960001123 epoprostenol Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000009442 healing mechanism Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004936 left thumb Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61243657A JPS6396129A (ja) | 1986-10-14 | 1986-10-14 | 創傷用治療水 |
| EP87305270A EP0254413A3 (fr) | 1986-06-13 | 1987-06-12 | Eau contenant des ions d'argent et ses applications |
| KR870009489A KR880002754A (ko) | 1986-08-29 | 1987-08-29 | 온이온수 및 그의 용도 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61243657A JPS6396129A (ja) | 1986-10-14 | 1986-10-14 | 創傷用治療水 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6396129A JPS6396129A (ja) | 1988-04-27 |
| JPH0124135B2 true JPH0124135B2 (fr) | 1989-05-10 |
Family
ID=17107071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61243657A Granted JPS6396129A (ja) | 1986-06-13 | 1986-10-14 | 創傷用治療水 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6396129A (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0595177A1 (fr) * | 1989-03-17 | 1994-05-04 | Klaus L. Buchholz | Procédé et dispositif pour obtenir un produit de réaction d'un gaz et d'un liquide |
| JP2001139477A (ja) * | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
| KR200200599Y1 (ko) * | 2000-03-31 | 2000-10-16 | 전인수 | 살균 및 항균용 은코팅 섬유종이 |
| KR100821231B1 (ko) * | 2001-08-09 | 2008-04-10 | 박시영 | 은(銀) 이온수 순간제조장치 |
| KR100492843B1 (ko) * | 2002-11-20 | 2005-06-02 | (주)나눅스 | 은 콜로이드 및 그 제조방법 |
| KR100614450B1 (ko) | 2004-07-15 | 2006-08-23 | 박형문 | 은(銀)을 이용한 살충제의 제조방법 |
| ES2635688T3 (es) * | 2004-10-07 | 2017-10-04 | Ngen Pharmaceuticals N.V. | Composición para el tratamiento de heridas y quemaduras |
| JP2011231052A (ja) * | 2010-04-28 | 2011-11-17 | Kracie Home Products Ltd | 皮膚外用剤組成物 |
| JP2014200778A (ja) * | 2013-04-10 | 2014-10-27 | 至明 松尾 | 抗酸化飲料水 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376764A (en) * | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
| JPS6061529A (ja) * | 1983-09-07 | 1985-04-09 | グイレーモ・エム・ヴエレツツ | 皮膚外傷治療用組成物及びその治療方法 |
-
1986
- 1986-10-14 JP JP61243657A patent/JPS6396129A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376764A (en) * | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
| JPS6061529A (ja) * | 1983-09-07 | 1985-04-09 | グイレーモ・エム・ヴエレツツ | 皮膚外傷治療用組成物及びその治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6396129A (ja) | 1988-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klokkevold et al. | The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits | |
| RU2289424C2 (ru) | Применение фармацевтической композиции, содержащей фактор эпидермального роста (ege), для предотвращения ампутации диабетической конечности | |
| Parkin et al. | Laser photocoagulation in hereditary hemorrhagic telangiectasia | |
| JPH0124135B2 (fr) | ||
| US20020049471A1 (en) | Method and hemostatic patch for effecting local hemostasis | |
| CN102018724A (zh) | 医用人工脑脊液的制备方法及应用 | |
| US8652509B2 (en) | Method of wound hemostasis using liquid gallium nitrate | |
| Zoucas et al. | Comparative evaluation of local hemostatic agents in experimental liver trauma: a study in the rat | |
| Hazarika | Oxidised regenerated cellulose: an effective emergency haemostatic in burns surgery | |
| RU2237473C1 (ru) | Способ лечения ран | |
| GLASSER et al. | Intra-arterial injection of penicillin for infections of the extremities: preliminary report | |
| RU2608431C1 (ru) | Способ закрытия дефектов вялотекущих ран нижних конечностей при синдроме диабетической стопы | |
| RU2290937C1 (ru) | Способ остановки носового кровотечения | |
| RU2125453C1 (ru) | Способ местного медикаментозного гемостаза | |
| RU2729025C1 (ru) | Способ хирургического лечения гнойно-воспалительных процессов костных и мягкотканых структур опорно-двигательной системы пациента с использованием мягких спейсеров, импрегнированных антибактериальными средствами | |
| RU2745965C1 (ru) | Способ профилактики послеоперационного спаечного процесса органов малого таза | |
| RU2311878C1 (ru) | Способ кожной пластики | |
| RU2065304C1 (ru) | Способ лечения трофических язв, осложненных микробной экземой | |
| SU1109168A1 (ru) | Способ обработки операционной раны | |
| RU2178311C1 (ru) | Способ лечения трофических язв венозного генеза | |
| JPS63112521A (ja) | 消化器粘膜疾患および角結膜炎の治療水 | |
| RU2223768C2 (ru) | Способ лечения гнойных ран | |
| RU2123806C1 (ru) | Способ хирургического лечения деструктивных форм панкреатита | |
| RU2150977C1 (ru) | Способ лечения острых воспалительных заболеваний органов брюшной полости и профилактики их осложнений | |
| RU2191585C2 (ru) | Способ стимуляции репаративной регенерации тканей при их повреждениях и заболеваниях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |